89Zr/177Lu-labeled claudin-6 antibody exhibits effective targeted radiodiagnostic and therapeutic efficacy in gynecological cancers

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

doi:10.1016/j.ejps.2026.107491

89Zr/177Lu-labeled claudin-6 antibody exhibits effective targeted radiodiagnostic and therapeutic efficacy in gynecological cancers

Xiaofei Hao & Xiaobo Du et al. · 2026-02-27

Claudin 6 (CLDN6) is highly expressed in ovarian cancer (OV) and uterine corpus endometrial cancer (UCEC) but silenced in normal tissues, holding promise as an attractive target for radioimmunotherapy (RIT). This study aimed to develop zirconium-89 (⁸⁹Zr)/lutetium-177 (¹⁷⁷Lu)-labeled CLDN6 antibody (IMAB027) for immuno-positron emission tomography (immuno-PET) and RIT for OV and UCEC subcutaneous tumor models. IMAB027 was conjugated with p-SCN-Bn-DFO and DOTA-maleimide, followed by radiolabeling with

Links

DOI PubMed

TL;DR

This study aimed to develop zirconium-89/lutetium-177 (⁸⁹Zr)/lutetium-177 (¹⁷⁷Lu)-labeled CLDN6 antibody (IMAB027) for immuno-positron emission tomography (immuno-PET) and RIT for OV and UCEC subcutaneous tumor models.

AI-generated by Semantic Scholar

Authors

Xiaofei Hao, Huan Du, Binwei Lin, Mingming Tang, Decai Wang, Huayan Zhang, Yu Zhang, Xia Yang, Xiaobo Du

Funding

National Natural Science Foundation of China Funding China Academy of Engineering Physics Funding